Corrigendum to: Glatiramer Acetate-Specific Antibody Titres in Patients with Relapsing / Remitting Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis: Glatiramer Acetate Antibodies and Clinical Outcome (Scandinavian Journal of Immunology, (2011), 74, 3, (219-226), 10.1111/j.1365-3083.2011.02581.x);Glatiramer acetate-specific antibody titres in patients with relapsing/Remitting multiple sclerosis and in experimental autoimmune encephalomyelitis

Scandinavian Journal of Immunology

Volumn 74, Issue 3, 2011, Pages 219-226

  Bomprezzi, R ^a   Schafer, R ^a   Reese, V ^b   Misra, A ^a   Vollmer, T L ^c   Kala, M ^d  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MITOXANTRONE;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 79961124371     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12673     Document Type: Erratum

References (30)

1. Noseworthy JHM, Lucchinetti CM, Rodriguez MM, Weinshenker BGM. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153-87.
3. Miller SD, Karpus WJ. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol Today 1994;15:356-61.
4. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-8.
5. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 1974;3:256-62.
6. Bornstein MB, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14.
7. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
8. Martinelli Boneschi F, Rovaris M, Johnson KP et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003;9:349-55.
9. Teitelbaum D, Brenner T, Abramsky O, Aharoni R, Sela M, Arnon R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003;9:592-9.
10. Brenner T, Arnon R, Sela M et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115:152-60.
11. Ure DR, Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 2002;16:1260-2.
12. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105:967-76.
13. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001;7:209-19.
14. Dhib-Jalbut S, Chen M, Said A, Zhan M, Johnson KP, Martin R. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 2003;140:163-71.
15. Kim HJ, Ifergan I, Antel JP et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004;172:7144-53.
16. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003;170:4483-8.
17. Jung S, Siglienti I, Grauer O, Magnus T, Scarlato G, Toyka K. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 2004;148:63-73.
18. Vollmer T, Panitch H, Bar-Or A et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663-70.
19. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
20. Arnold DL, Campagnolo D, Panitch H et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 2008;255:1473-8.
21. Basile E, Gibbs E, Aziz T, Oger J. During 3years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006;177:161-6.
22. Bar-Or A, Oger J, Gibbs E et al. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler 2009;15:959-64.
23. Farina C, Vargas V, Heydari N, Kumpfel T, Meinl E, Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002;123:188-92.
24. Lucisano Valim YM, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 1991;84:1-8.
25. Azeredo da SS, Kikuchi S, Fossati-Jimack L et al. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 2002;195:665-72.
26. Krishnamoorthy G, Wekerle H. EAE: an immunologist's magic eye. Eur J Immunol 2009;39:2031-5.
27. Weber MS, Prod'homme T, Youssef S et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935-43.
28. Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 2010;221:136-45.
29. Jee Y, Piao WH, Liu R et al. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 2007;125:34-42.
30. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998;160:3555-61.